Publications by authors named "S Bouzid Rekik"
Introduction: This study aims to investigate the efficacy and tolerance of biologic disease-modifying anti-rheumatic drug (bDMARDs) in the current management of rheumatoid arthritis (RA) by identifying the retention time and survival rate of bDMARDs.
Materials And Methods: We conducted a retrospective cohort study including Tunisian patients initiating bDMARD treatment between 2016 and 2018 whose data were collected from the National Health Insurance Fund (NHIF). The NHIF is the national office which organises and centralises patients under bDMARDs from all over the country.
Article Synopsis
- * The research investigates the effects of adding paternal lymphocytes to maternal activated PBMCs during insemination, with patients divided into four groups based on the type and number of PBMCs used.
- * Results indicate that using activated PBMCs increases clinical pregnancy rates across all groups, with the highest success observed in patients receiving both paternal and maternal activated PBMCs, achieving a clinical pregnancy rate of 47.2% and live birth rate of 41.
Sarcocystis spp. are apicomplexan cyst-forming parasites that can infect numerous vertebrates, including birds. Sarcosporidiosis infection was investigated in three muscles (breast, right and left thigh muscle) and one organ (heart) of four Razorbill auks (Alca torda) stranded between November and December 2022 on the shores of the Mediterranean Sea in Nabeul and Bizerte governorates, Northern Tunisia.
View Article and Find Full Text PDFA Review on Crimean-Congo Hemorrhagic Fever Infections in Tunisia.
Vector Borne Zoonotic Dis
June 2024
Crimean-Congo hemorrhagic fever (CCHF) is a zoonotic tick-borne disease, caused by an arbovirus of the genus Orthonairovirus and the family Nairoviridae. Crimean-Congo hemorrhagic fever virus (CCHFV) is widespread in several regions of the world. While the virus is not pathogenic to all susceptible livestock and wild mammals, it can lead to severe hemorrhagic fever in humans.
View Article and Find Full Text PDFArticle Synopsis
- TNF alpha blockers like infliximab (IFX) and adalimumab (ADA) are effective for inflammatory diseases but about 30% of patients don't respond, possibly due to anti-drug antibodies (ADAbs).
- A study involving 197 patients found that 40% of those on IFX and 25% on ADA tested positive for ADAbs, with varying rates across conditions (RA, SpA, and CD).
- Despite the presence of ADAbs being linked to lower drug levels, they did not correlate with disease activity, suggesting that other factors besides immunogenicity may influence treatment failures.